What is GBM Agile?

When you or someone you love is diagnosed with glioblastoma, the question comes fast: Is there a trial I should be in? The internet offers a wall of options. It can feel impossible to parse.

GBM AGILE is a trial that tests multiple treatments at once, routes patients to the arms most likely to benefit their specific tumor type, and is open right now at locations around the world, including sites across the United States.

What Is GBM AGILE?

GBM AGILE stands for Glioblastoma Adaptive, Global, Innovative Learning Environment. According to ClinicalTrials.gov (NCT03970447), it is "an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM."

That's a lot of words. Here's what it means in plain language:

• Phase 2/3 means the trial is past the early safety stage. Phase 2 tests whether a treatment works well enough to study further. Phase 3 is the final stage before a possible FDA approval pathway. It compares the intervention in question rigorously against standard care. GBM AGILE runs both phases as one continuous process, which saves time.
• Adaptive means the trial learns as it goes. If early data shows a particular treatment is performing well, or poorly, for a specific group of patients, the trial adjusts how many people are assigned to that arm. More patients are steered toward what's working.
• Platform means multiple experimental treatments are evaluated under one shared framework, rather than running separate trials for each drug. Patients enter the platform, and the trial's design figures out where they best fit.

The sponsor is the Global Coalition for Adaptive Research, and the Global Principal Investigator is Tim Cloughesy, MD, also listed as GCAR's Chief Medical Officer.

Who Can Enroll?

GBM AGILE accepts both newly diagnosed and recurrent GBM patients. The eligibility requirements below come directly from ClinicalTrials.gov (NCT03970447).

Newly Diagnosed GBM

To be considered, you generally need to:

• Be 18 years of age or older
• Have a histologically confirmed Grade IV GBM, including gliosarcoma, that is IDH wild-type (confirmed by tissue testing)
• Have a Karnofsky Performance Status of 60% or higher — a standard scale doctors use to assess functional ability
• Have tumor tissue available from your surgery or biopsy
• Have an MRI scan within 21 days prior to randomization (your post-surgical MRI may qualify)

Recurrent GBM

If your GBM has come back, you may be eligible if you:

• Are 18 years of age or older
• Have histologically confirmed Grade IV GBM at first or second recurrence after prior treatment that included at least radiation therapy
• Have evidence of progression confirmed by two scans — one at the time of progression, one prior to it
• Have a Karnofsky Performance Status of 70% or higher

These are general criteria summarized from the trial record. Your oncologist and the trial's research coordinators will review your full medical history before any enrollment decision is made.

What This Means for Patients

In a conventional trial, a patient enrolls in a study testing one specific drug. GBM AGILE's platform design means that when you enroll, the trial uses your tumor's molecular profile to match you to the arm most relevant to your biology. The goal, as stated in the trial record, is to "identify effective therapies for glioblastoma and match effective therapies with patient subtypes."

For patients who've just received a diagnosis and feel overwhelmed by options, this matters. You aren't betting everything on one experimental drug based on limited information. The trial is built to route you toward what the data — including data from patients who enrolled before you — suggests may be most relevant.

62 sites are currently open. According to ClinicalTrials.gov, active recruiting US locations include:

• University of Alabama at Birmingham (Birmingham, AL)
• University of California, San Diego (La Jolla, CA)
• Cedars-Sinai / Samuel Oschin Comprehensive Cancer Institute (Los Angeles, CA)
• University of California, Los Angeles (Los Angeles, CA)
• University of California, San Francisco (San Francisco, CA)
• St. Joseph Hospital (Orange, CA)
• University of Colorado Denver (Aurora, CO)
• Yale Cancer Center / Smilow Cancer Hospital (New Haven, CT)

That's a partial list. If you're not near any of those cities, other sites may be open near you. The ClinicalTrials.gov listing has the full directory.

The primary endpoint is overall survival. According to the trial record, the study measures overall survival — how long patients live from the time of randomization — tracked through approximately two years following the last patient enrolled. This is the most meaningful endpoint a trial can use.

Timing matters, especially for newly diagnosed patients. The newly diagnosed arm requires an MRI within 21 days before randomization and tumor tissue from surgery. These windows mean that the conversation about this trial should happen early — ideally before or immediately after surgery, not months later. If someone you love was recently diagnosed, it's worth asking the neurosurgeon or neuro-oncologist about GBM AGILE at the next appointment.

What Enrollment Actually Looks Like

Joining a clinical trial always begins with a screening process. For GBM AGILE, that means:

1. Confirming eligibility — your care team reviews your pathology report, performance status, imaging, and prior treatment history against the criteria above
2. Tissue review — your tumor sample from surgery or biopsy is assessed to confirm GBM diagnosis and IDH wild-type status
3. Imaging — a qualifying MRI must be on file
4. Randomization — once enrolled, you are assigned to a treatment arm based on your tumor's characteristics and the trial's adaptive algorithm

Because the trial runs across dozens of sites under a shared master protocol, enrollment processes are standardized. That can make the logistics more predictable than smaller, single-institution studies.

How to Learn More or Find Out If You Qualify

Clinical trials are research. They are not a guarantee of benefit, and enrollment is never automatic. But for patients with GBM — newly diagnosed or recurrent — GBM AGILE represents a carefully structured, internationally coordinated effort to test multiple treatments efficiently and match patients to the arms most relevant to their tumor.

If you or someone you love may be eligible, here are your next steps:

• Talk to your neuro-oncologist — ask specifically about GBM AGILE and whether it fits your current treatment timeline
• Review the full trial listing on ClinicalTrials.gov: NCT03970447
• Use PACT AI to search for GBM trials based on your specific situation, including this one: pact-ai.com

---

Frequently Asked Questions

What does "adaptive randomization" mean for a patient?

In most trials, patients are assigned to treatment groups randomly, like a coin flip. Adaptive randomization adjusts those odds over time based on accumulating data. If one arm is showing stronger signals for a particular patient subtype, more patients with that profile may be directed there. According to the trial record, GBM AGILE uses this method to "efficiently identify" effective therapies.

Can I join GBM AGILE if my GBM has come back after treatment?

Yes. The trial has a separate recurrent GBM arm for patients at first or second recurrence who have previously received radiation therapy and meet the performance status and imaging criteria outlined above. Your care team can help determine whether you qualify.

How many locations are part of this trial?

According to ClinicalTrials.gov, GBM AGILE is open at 62 locations globally, with multiple actively recruiting US sites across Alabama, California, Colorado, Connecticut, and more.

Who is running this trial?

The trial is sponsored by the Global Coalition for Adaptive Research. The Global Principal Investigator listed on ClinicalTrials.gov is Tim Cloughesy, MD, who serves as GCAR's Chief Medical Officer.

---

This post is for informational purposes only and does not constitute medical advice.